Overexpression-mediated activation of MET in the Golgi promotes HER3/ERBB3 phosphorylation

Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma

(2017) Manish A. Shah et al.   JAMA Oncology

Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment

(2016) Puyu Shi et al.   CANCER LETTERS

A First-in-Human Phase I Study of a Bivalent MET Antibody, Emibetuzumab (LY2875358), as Monotherapy and in Combination with Erlotinib in Advanced Cancer

(2016) Lee S. Rosen et al.   CLINICAL CANCER RESEARCH

Acid sphingomyelinase is required for cell surface presentation of Met receptor tyrosine kinase in cancer cells

(2016) Linyu Zhu et al.   JOURNAL OF CELL SCIENCE

Preclinical Evaluation of AMG 337, a Highly Selective Small Molecule MET Inhibitor, in Hepatocellular Carcinoma

(2016) Zhiqiang Du et al.   MOLECULAR CANCER THERAPEUTICS

Dual Constant Domain-Fab: A novel strategy to improve half-life and potency of a Met therapeutic antibody

(2016) Simona Cignetto et al.   Molecular Oncology

A Randomized Phase II Study of FOLFOX With or Without the MET Inhibitor Onartuzumab in Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction

(2016) M. A. Shah et al.   ONCOLOGIST

Randomized, phase II, placebo-controlled trial of onartuzumab and/or bevacizumab in combination with weekly paclitaxel in patients with metastatic triple-negative breast cancer

(2015) V. Diéras et al.   ANNALS OF ONCOLOGY

Prognostic significance of c-Met in breast cancer: a meta-analysis of 6010 cases

(2015) Shunchao Yan et al.   Diagnostic Pathology

Predictive and prognostic value of de novo MET expression in patients with advanced non-small-cell lung cancer

(2015) Anna Li et al.   LUNG CANCER

The EGFR/ErbB3 Pathway Acts as a Compensatory Survival Mechanism upon c-Met Inhibition in Human c-Met+ Hepatocellular Carcinoma

(2015) Steven N. Steinway et al.   PLoS One

MET expression and copy number heterogeneity in nonsquamous non-small cell lung cancer (nsNSCLC)

(2015) David Casadevall et al.   Oncotarget

Essential role of Her3 in two signaling transduction patterns: Her2/Her3 and MET/Her3 in proliferation of human gastric cancer

(2014) Chen Yun et al.   MOLECULAR CARCINOGENESIS

Crosstalk Between Nuclear MET and SOX9/β-Catenin Correlates with Castration-Resistant Prostate Cancer

(2014) Yingqiu Xie et al.   MOLECULAR ENDOCRINOLOGY

MET Gene Copy Number Predicts Worse Overall Survival in Patients with Non-Small Cell Lung Cancer (NSCLC); A Systematic Review and Meta-Analysis

(2014) Anastasios Dimou et al.   PLoS One

How IGF-1 activates its receptor

(2014) Jennifer M Kavran et al.   eLife

How insulin engages its primary binding site on the insulin receptor

(2013) John G. Menting et al.   NATURE

Met degradation: more than one stone to shoot a receptor down

(2012) Jonathan Lefebvre et al.   FASEB JOURNAL

c-Met function requires n-linked glycosylation modification of pro-Met

(2012) Run Chen et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Differential roles of trans-phosphorylated EGFR, HER2, HER3 and RET as heterodimerisation partners of MET in lung cancer with MET amplification

(2011) J Tanizaki et al.   BRITISH JOURNAL OF CANCER

Toward the Prognostic Significance and Therapeutic Potential of HER3 Receptor Tyrosine Kinase in Human Colon Cancer

(2011) A. Beji et al.   CLINICAL CANCER RESEARCH

A Novel Kinase Inhibitor, INCB28060, Blocks c-MET-Dependent Signaling, Neoplastic Activities, and Cross-Talk with EGFR and HER-3

(2011) X. Liu et al.   CLINICAL CANCER RESEARCH

Foretinib (GSK1363089), a multi-kinase inhibitor of MET and VEGFRs, inhibits growth of gastric cancer cell lines by blocking inter-receptor tyrosine kinase networks

(2011) Yu Kataoka et al.   INVESTIGATIONAL NEW DRUGS

The constitutive activity of the ALK mutated at positions F1174 or R1275 impairs receptor trafficking

(2011) P Mazot et al.   ONCOGENE

Association of constitutively activated hepatocyte growth factor receptor (Met) with resistance to a dual EGFR/Her2 inhibitor in non-small-cell lung cancer cells

(2009) S Agarwal et al.   BRITISH JOURNAL OF CANCER

The MET Receptor Tyrosine Kinase Is a Potential Novel Therapeutic Target for Head and Neck Squamous Cell Carcinoma

(2009) T. Y. Seiwert et al.   CANCER RESEARCH

Mechanism for Activation of the EGF Receptor Catalytic Domain by the Juxtamembrane Segment

(2009) Natalia Jura et al.   CELL

The Aberrant Localization of Oncogenic Kit Tyrosine Kinase Receptor Mutants Is Reversed on Specific Inhibitory Treatment

(2009) H. Bougherara et al.   MOLECULAR CANCER RESEARCH

Mislocalized Activation of Oncogenic RTKs Switches Downstream Signaling Outcomes

(2009) Chunaram Choudhary et al.   MOLECULAR CELL

Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3

(2009) N. Jura et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

KIT Mutations Induce Intracellular Retention and Activation of an Immature Form of the KIT Protein in Gastrointestinal Stromal Tumors

(2008) S. Tabone-Eglinger et al.   CLINICAL CANCER RESEARCH

Receptor trafficking controls weak signal delivery: a strategy used by c-Met for STAT3 nuclear accumulation

(2008) Stéphanie Kermorgant et al.   JOURNAL OF CELL BIOLOGY

Signaling networks assembled by oncogenic EGFR and c-Met

(2008) A. Guo et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA